The Science Journal of the American Association for Respiratory Care

2011 OPEN FORUM Abstracts


Patricia A. Dailey1, Kyle Walsh2; 1Respiratory Care, Baystate Medical Center, Springfield, MA; 2Clinical Engineering, Baystate Medical Center, Springfield, MA

INTRODUCTION: The advent of new aerosol technology (vibrating mesh) for continuous aerosol therapy has redefined the term continuous aerosol therapy1 and given us the ability to quantify lung dose2. Revisions to the vibrating mesh (Aeroneb Solo) currently in development raised the question as to how the changes would effect aerosol production. Our objective was to determine how the modifications would effect aerosol run and pause times as compared to the original design. METHOD: A pulmonary infusion pump (CME America 575 BodyGuard) with a dedicated infusion set was used to deliver solution (nss) to a vibrating mesh nebulizer (Aerogen® Aeroneb Solo). Both the original vibrating mesh (Solo) and the revised model (Solo II) were evaluated, at flow rates of 4 ml and 12 ml per hour. Aerosol production and pauses were observed and timed. RESULTS: Aerosol pause times in seconds for the original design (Solo) versus revised design (Solo II) at 4 ml per hour (118.3 ± 29 vs. 119 ± 1.2). Aerosol run times ± 19.2 vs. 18.6 ± 2.1) at 12 ml per hour (125.1 ± 48.5 vs. 18.3 ± 0.6). The aerosol run time for the Solo II was 9 times more consistent at 4 ml per hour and 80 times more consistent at 12 ml per hour. The pause time for the Solo II was 4.5 times more consistent at 4 ml per hour and 8.4 times more consistent at 12 ml per hour. CONCLUSIONS: Standard deviation on both run and pause times for the Solo II were significantly lower allowing for increased accuracy of aerosolized medication delivery. Large standard deviations in aerosol pauses could lead to under and/or over medicating. The significantly lower variability in pause times with the new design allows for safer and more precise delivery of aerosolized medication. 1. Dailey P, Walsh K, Thongpradit P, Aerosol Pause Times Associated With Vibrating Mesh Nebulizer. . Resp Care 2010 November 2. Dailey P, Raghunathan K, Thongpradit P, Walsh, K, Fink J. A Mathematical Model for Achieving Target Lung Dose of Prostacyclins. Resp Care 2010 November Sponsored Research – None